|
|
Activation of phagocytosis by immune checkpoint blockade |
Chia-Wei Li1, Yun-Ju Lai2, Jennifer L. Hsu1, Mien-Chie Hung1() |
1. Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA 2. Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA |
|
|
Abstract Inhibition of macrophage-mediated phagocytosis has emerged as an essential mechanism for tumor immune evasion. One mechanism inhibiting the innate response is the presence of the macrophage inhibitory molecule, signal regulatory protein-α (SIRPα), on tumor-associated macrophages (TAMs) and its cognate ligand cluster of differentiation 47 (CD47) on tumor cells in the tumor microenvironment. On the basis of a recently discovered programmed death protein 1 (PD-1) in TAMs, we discuss the potential inhibitory receptors that possess new functions beyond T cell exhaustion in this review. As more and more immune receptors are found to be expressed on TAMs, the corresponding therapies may also stimulate macrophages for phagocytosis and thereby provide extra anti-tumor benefits in cancer therapy. Therefore, identification of biomarkers and combinatorial therapeutic strategies, have the potential to improve the efficacy and safety profiles of current immunotherapies.
|
Keywords
CD47
PD-1
PD-L1
immunotherapy
TAM
phagocytosis
macrophage
|
Corresponding Author(s):
Mien-Chie Hung
|
Just Accepted Date: 09 July 2018
Issue Date: 03 September 2018
|
|
1 |
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12(4): 252–264
https://doi.org/10.1038/nrc3239
pmid: 22437870
|
2 |
Morrissey KM, Yuraszeck TM, Li CC, Zhang Y, Kasichayanula S. Immunotherapy and novel combinations in oncology: current landscape, challenges, and opportunities. Clin Transl Sci 2016; 9(2): 89–104
https://doi.org/10.1111/cts.12391
pmid: 26924066
|
3 |
Li CW, Lim SO, Hsu JL, Hung MC. Rational combination of immunotherapy for triple negative breast cancer treatment. Chin Clin Oncol 2017; 6(5): 54
https://doi.org/10.21037/cco.2017.08.04
pmid: 29129094
|
4 |
Iwai Y, Hamanishi J, Chamoto K, Honjo T. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci 2017; 24(1): 26
https://doi.org/10.1186/s12929-017-0329-9
pmid: 28376884
|
5 |
Alexander W, The checkpoint immunotherapy revolution: what started as a trickle has become a flood, despite some daunting adverse effects; new drugs, indications, and combinations continue to emerge. P T 2016; 41(3):185–191
pmid: 26957887
|
6 |
Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med 2016; 8(328): 328rv4
https://doi.org/10.1126/scitranslmed.aad7118
pmid: 26936508
|
7 |
Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 2017; 168(4): 707–723
https://doi.org/10.1016/j.cell.2017.01.017
pmid: 28187290
|
8 |
Spain L, Walls G, Julve M, O’Meara K, Schmid T, Kalaitzaki E, Turajlic S, Gore M, Rees J, Larkin J. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol 2017; 28(2): 377–385
pmid: 28426103
|
9 |
Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, Traver D, van Rooijen N, Weissman IL. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 2009; 138(2): 271–285
https://doi.org/10.1016/j.cell.2009.05.046
pmid: 19632178
|
10 |
Jiang P, Lagenaur CF, Narayanan V. Integrin-associated protein is a ligand for the P84 neural adhesion molecule. J Biol Chem 1999; 274(2): 559–562
https://doi.org/10.1074/jbc.274.2.559
pmid: 9872987
|
11 |
Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr, van Rooijen N, Weissman IL. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009; 138(2): 286–299
https://doi.org/10.1016/j.cell.2009.05.045
pmid: 19632179
|
12 |
Baccelli I, Stenzinger A, Vogel V, Pfitzner BM, Klein C, Wallwiener M, Scharpff M, Saini M, Holland-Letz T, Sinn HP, Schneeweiss A, Denkert C, Weichert W, Trumpp A. Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients. Oncotarget 2014; 5(18): 8147–8160
https://doi.org/10.18632/oncotarget.2385
pmid: 25230070
|
13 |
Nagahara M1, Mimori K, Kataoka A, Ishii H, Tanaka F, Nakagawa T, Sato T, Ono S, Sugihara K, Mori M. Correlated expression of CD47 and SIRPA in bone marrow and in peripheral blood predicts recurrence in breast cancer patients. Clin Cancer Res 2010; 16(18): 4625–4635.
https://doi.org/10.1158/1078-0432.CCR-10-0349
pmid: :2070561335
|
14 |
Suzuki S, Yokobori T, Tanaka N, Sakai M, Sano A, Inose T, Sohda M, Nakajima M, Miyazaki T, Kato H, Kuwano H. CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma. Oncol Rep 2012; 28(2): 465–472
https://doi.org/10.3892/or.2012.1831
pmid: 22641236
|
15 |
Yoshida K, Tsujimoto H, Matsumura K, Kinoshita M, Takahata R, Matsumoto Y, Hiraki S, Ono S, Seki S, Yamamoto J, Hase K. CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer. Cancer Med 2015; 4(9): 1322–1333
https://doi.org/10.1002/cam4.478
pmid: 26077800
|
16 |
Wang H, Tan M, Zhang S, Li X, Gao J, Zhang D, Hao Y, Gao S, Liu J, Lin B. Expression and significance of CD44, CD47 and c-met in ovarian clear cell carcinoma. Int J Mol Sci 2015; 16(2): 3391–3404
https://doi.org/10.3390/ijms16023391
pmid: 25658794
|
17 |
Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, Gupta R, Tsai JM, Sinha R, Corey D, Ring AM, Connolly AJ, Weissman IL. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 2017; 545(7655): 495–499
https://doi.org/10.1038/nature22396
pmid: 28514441
|
18 |
Liu X, Kwon H, Li Z, Fu YX. Is CD47 an innate immune checkpoint for tumor evasion? J Hematol Oncol 2017; 10(1): 12
https://doi.org/10.1186/s13045-016-0381-z
pmid: 28077173
|
19 |
Barkal AA, Weiskopf K, Kao KS, Gordon SR, Rosental B, Yiu YY, George BM, Markovic M, Ring NG, Tsai JM, McKenna KM, Ho PY, Cheng RZ, Chen JY, Barkal LJ, Ring AM, Weissman IL, Maute RL. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nat Immunol 2018; 19(1): 76–84
https://doi.org/10.1038/s41590-017-0004-z
pmid: 29180808
|
20 |
Riley JL. PD-1 signaling in primary T cells. Immunol Rev 2009; 229(1): 114–125
https://doi.org/10.1111/j.1600-065X.2009.00767.x
pmid: 19426218
|
21 |
Fuertes Marraco SA, Neubert NJ, Verdeil G, Speiser DE. Inhibitory receptors beyond T cell exhaustion. Front Immunol 2015; 6: 310
https://doi.org/10.3389/fimmu.2015.00310
pmid: 26167163
|
22 |
Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 2015; 125(9): 3384–3391
https://doi.org/10.1172/JCI80011
pmid: 26325035
|
23 |
Riella LV, Paterson AM, Sharpe AH, Chandraker A. Role of the PD-1 pathway in the immune response. Am J Transplant 2012; 12(10): 2575–2587
https://doi.org/10.1111/j.1600-6143.2012.04224.x
pmid: 22900886
|
24 |
Lim SO, Li CW, Xia W, Cha JH, Chan LC, Wu Y, Chang SS, Lin WC, Hsu JM, Hsu YH, Kim T, Chang WC, Hsu JL, Yamaguchi H, Ding Q, Wang Y, Yang Y, Chen CH, Sahin AA, Yu D, Hortobagyi GN, Hung MC. Deubiquitination and stabilization of PD-L1 by CSN5. Cancer Cell 2016; 30(6): 925–939
https://doi.org/10.1016/j.ccell.2016.10.010
pmid: 27866850
|
25 |
Liu X, Pu Y, Cron K, Deng L, Kline J, Frazier WA, Xu H, Peng H, Fu YX, Xu MM. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med 2015; 21(10): 1209–1215
https://doi.org/10.1038/nm.3931
pmid: 26322579
|
26 |
Soto-Pantoja DR, Terabe M, Ghosh A, Ridnour LA, DeGraff WG, Wink DA, Berzofsky JA, Roberts DD. CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy. Cancer Res 2014; 74(23): 6771–6783
https://doi.org/10.1158/0008-5472.CAN-14-0037-T
pmid: 25297630
|
27 |
Yang L, Zhang Y. Tumor-associated macrophages: from basic research to clinical application. J Hematol Oncol 2017; 10(1): 58
https://doi.org/10.1186/s13045-017-0430-2
pmid: 28241846
|
28 |
Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity 2014; 41(1): 49–61
https://doi.org/10.1016/j.immuni.2014.06.010
pmid: 25035953
|
29 |
Alderton GK. Tumour immunology: turning macrophages on, off and on again. Nat Rev Immunol 2014; 14(3): 136–137
https://doi.org/10.1038/nri3634
pmid: 24566906
|
30 |
Zijlmans HJ, Fleuren GJ, Baelde HJ, Eilers PH, Kenter GG, Gorter A. The absence of CCL2 expression in cervical carcinoma is associated with increased survival and loss of heterozygosity at 17q11.2. J Pathol 2006; 208(4): 507–517
https://doi.org/10.1002/path.1918
pmid: 16435282
|
31 |
Tsutsui S, Yasuda K, Suzuki K, Tahara K, Higashi H, Era S. Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep 2005; 14(2): 425–431
pmid: 16012726
|
32 |
Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, Jones T, Jucknischke U, Scheiblich S, Kaluza K, Gorr IH, Walz A, Abiraj K, Cassier PA, Sica A, Gomez-Roca C, de Visser KE, Italiano A, Le Tourneau C, Delord JP, Levitsky H, Blay JY, Rüttinger D. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 2014; 25(6): 846–859
https://doi.org/10.1016/j.ccr.2014.05.016
pmid: 24898549
|
33 |
Mok S, Koya RC, Tsui C, Xu J, Robert L, Wu L, Graeber T, West BL, Bollag G, Ribas A. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res 2014; 74(1): 153–161
https://doi.org/10.1158/0008-5472.CAN-13-1816
pmid: 24247719
|
34 |
Han Y, Chen Z, Yang Y, Jiang Z, Gu Y, Liu Y, Lin C, Pan Z, Yu Y, Jiang M, Zhou W, Cao X. Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma. Hepatology 2014; 59(2): 567–579
https://doi.org/10.1002/hep.26694
pmid: 23960017
|
35 |
Komohara Y, Jinushi M, Takeya M. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci 2014; 105(1): 1–8
https://doi.org/10.1111/cas.12314
pmid: 24168081
|
36 |
Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, Khoo KH, Chang SS, Cha JH, Kim T, Hsu JL, Wu Y, Hsu JM, Yamaguchi H, Ding Q, Wang Y, Yao J, Lee CC, Wu HJ, Sahin AA, Allison JP, Yu D, Hortobagyi GN, Hung MC. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun 2016; 7: 12632
https://doi.org/10.1038/ncomms12632
pmid: 27572267
|
37 |
Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, Hsu JL, Yu WH, Du Y, Lee HH, Li CW, Chou CK, Lim SO, Chang SS, Litton J, Arun B, Hortobagyi GN, Hung MC. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res 2017; 23(14): 3711–3720
https://doi.org/10.1158/1078-0432.CCR-16-3215
pmid: 28167507
|
38 |
Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira NT, Tan Y, Ci Y, Wu F, Dai X, Guo J, Huang YH, Fan C, Ren S, Sun Y, Freeman GJ, Sicinski P, Wei W. Cyclin D-CDK4 kinase destabilizes PD-L1 via Cul3(SPOP) to control cancer immune surveillance. Nature 2017; 553(7686): 91–95
https://doi.org/10.1038/nature25015
|
39 |
Burr ML, Sparbier CE, Chan YC, Williamson JC, Woods K, Beavis PA, Lam EYN, Henderson MA, Bell CC, Stolzenburg S, Gilan O, Bloor S, Noori T, Morgens DW, Bassik MC, Neeson PJ, Behren A, Darcy PK, Dawson SJ, Voskoboinik I, Trapani JA, Cebon J, Lehner PJ, Dawson MA. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature 2017; 549(7670): 101–105
https://doi.org/10.1038/nature23643
pmid: 28813417
|
40 |
Mezzadra R, Sun C, Jae LT, Gomez-Eerland R, de Vries E, Wu W, Logtenberg MEW, Slagter M, Rozeman EA, Hofland I, Broeks A, Horlings HM, Wessels LFA, Blank CU, Xiao Y, Heck AJR, Borst J, Brummelkamp TR, Schumacher TNM. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature 2017; 549(7670): 106–110
https://doi.org/10.1038/nature23669
pmid: 28813410
|
41 |
Li CW, Lim SO, Chung EM, Kim YS, Park AH, Yao J, Cha JH, Xia W, Chan LC, Kim T, Chang SS, Lee HH, Chou CK, Liu YL, Yeh HC, Perillo EP, Dunn AK, Kuo CW, Khoo KH, Hsu JL, Wu Y, Hsu JM, Yamaguchi H, Huang TH, Sahin AA, Hortobagyi GN, Yoo SS, Hung MC. Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1. Cancer Cell 2018; 33(2):187–201.e10
https://doi.org/10.1016/j.ccell.2018.01.009
pmid: 29438695
|
42 |
Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5(12): 1365–1369
https://doi.org/10.1038/70932
pmid: 10581077
|
43 |
Rodríguez-García M, Porichis F, de Jong OG, Levi K, Diefenbach TJ, Lifson JD, Freeman GJ, Walker BD, Kaufmann DE, Kavanagh DG. Expression of PD-L1 and PD-L2 on human macrophages is up-regulated by HIV-1 and differentially modulated by IL-10. J Leukoc Biol 2011; 89(4): 507–515
https://doi.org/10.1189/jlb.0610327
pmid: 21097698
|
44 |
Wu K, Kryczek I, Chen L, Zou W, Welling TH. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. Cancer Res 2009; 69(20): 8067–8075
https://doi.org/10.1158/0008-5472.CAN-09-0901
pmid: 19826049
|
45 |
Xiao Y, Yu S, Zhu B, Bedoret D, Bu X, Francisco LM, Hua P, Duke-Cohan JS, Umetsu DT, Sharpe AH, DeKruyff RH, Freeman GJ. RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J Exp Med 2014; 211(5): 943–959
https://doi.org/10.1084/jem.20130790
pmid: 24752301
|
46 |
Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P, Curiel T, Myers L, Lackner A, Alvarez X, Ochoa A, Chen L, Zou W. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006; 203(4): 871–881
https://doi.org/10.1084/jem.20050930
pmid: 16606666
|
47 |
Dangaj D, Lanitis E, Zhao A, Joshi S, Cheng Y, Sandaltzopoulos R, Ra HJ, Danet-Desnoyers G, Powell DJ Jr, Scholler N. Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses. Cancer Res 2013; 73(15): 4820–4829
https://doi.org/10.1158/0008-5472.CAN-12-3457
pmid: 23722540
|
48 |
Dong J, Cheng L, Zhao M, Pan X, Feng Z, Wang D. Tim-3-expressing macrophages are functionally suppressed and expanded in oral squamous cell carcinoma due to virus-induced Gal-9 expression. Tumour Biol 2017; 39(5): 1010428317701651
https://doi.org/10.1177/1010428317701651
pmid: 28466780
|
49 |
Li H, Wu K, Tao K, Chen L, Zheng Q, Lu X, Liu J, Shi L, Liu C, Wang G, Zou W. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology 2012; 56(4): 1342–1351
https://doi.org/10.1002/hep.25777
pmid: 22505239
|
50 |
Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, Tom I, Ivelja S, Refino CJ, Clark H, Eaton D, Grogan JL. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol 2009; 10(1): 48–57
https://doi.org/10.1038/ni.1674
pmid: 19011627
|
51 |
Li M, Xia P, Du Y, Liu S, Huang G, Chen J, Zhang H, Hou N, Cheng X, Zhou L, Li P, Yang X, Fan Z. T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-g production of natural killer cells via b-arrestin 2-mediated negative signaling. J Biol Chem 2014; 289(25): 17647–17657
https://doi.org/10.1074/jbc.M114.572420
pmid: 24817116
|
52 |
Tahara-Hanaoka S, Shibuya K, Onoda Y, Zhang H, Yamazaki S, Miyamoto A, Honda S, Lanier LL, Shibuya A. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112). Int Immunol 2004; 16(4): 533–538
https://doi.org/10.1093/intimm/dxh059
pmid: 15039383
|
53 |
Guillemin GJ, Brew BJ. Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification. J Leukoc Biol 2004; 75(3): 388–397
https://doi.org/10.1189/jlb.0303114
pmid: 14612429
|
54 |
Zhu Y, Paniccia A, Schulick AC, Chen W, Koenig MR, Byers JT, Yao S, Bevers S, Edil BH. Identification of CD112R as a novel checkpoint for human T cells. J Exp Med 2016; 213(2): 167–176
https://doi.org/10.1084/jem.20150785
pmid: 26755705
|
55 |
Galdiero M, Pisciotta MG, Gorga F, Petrillo G, Marinelli A, Galdiero E. Modulation of costimulatory molecules CD80/CD86 on B cells and macrophages by stress proteins GroEL, GroES and DnaK. Int J Immunopathol Pharmacol 2005; 18(4): 637–644
https://doi.org/10.1177/039463200501800404
pmid: 16388710
|
56 |
Zang X, Allison JP. The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res. 2007; 13(18 Pt 1): 5271–5279
https://doi.org/DOI:0.1158/1078-0432.CCR-07-1030
pmid: 17875755
|
57 |
Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, Lovelace P, Scheeren FA, Chao MP, Weiskopf K, Tang C, Volkmer AK, Naik TJ, Storm TA, Mosley AR, Edris B, Schmid SM, Sun CK, Chua MS, Murillo O, Rajendran P, Cha AC, Chin RK, Kim D, Adorno M, Raveh T, Tseng D, Jaiswal S, Enger PO, Steinberg GK, Li G, So SK, Majeti R, Harsh GR, van de Rijn M, Teng NN, Sunwoo JB, Alizadeh AA, Clarke MF, Weissman IL. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 2012; 109(17): 6662–6667
https://doi.org/10.1073/pnas.1121623109
pmid: 22451913
|
58 |
Wang Q, Zhang P, Zhang Q, Wang X, Li J, Ma C, Sun W, Zhang L. Analysis of CD137 and CD137L expression in human primary tumor tissues. Croat Med J 2008; 49(2): 192–200
https://doi.org/10.3325/cmj.2008.2.192
pmid: 18461674
|
59 |
Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, Weiskopf K, Willingham SB, Raveh T, Park CY, Majeti R, Weissman IL. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2010; 2(63):63ra94
https://doi.org/10.1126/scitranslmed.3001375
pmid: 21178137
|
60 |
Leclerc E, Fritz G, Vetter SW, Heizmann CW. Binding of S100 proteins to RAGE: an update. Biochim Biophys Acta 2009; 1793(6): 993–1007
https://doi.org/10.1016/j.bbamcr.2008.11.016
pmid: 19121341
|
61 |
Kinouchi M, Miura K, Mizoi T, Ishida K, Fujibuchi W, Sasaki H, Ohnuma S, Saito K, Katayose Y, Naitoh T, Motoi F, Shiiba K, Egawa S, Shibata C, Unno M. Infiltration of CD40-positive tumor-associated macrophages indicates a favorable prognosis in colorectal cancer patients. Hepatogastroenterology 2013; 60(121): 83–88
pmid: 22687258
|
62 |
Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 2009; 229(1): 152–172
https://doi.org/10.1111/j.1600-065X.2009.00782.x
pmid: 19426221
|
63 |
Karulf M, Kelly A, Weinberg AD, Gold JA. OX40 ligand regulates inflammation and mortality in the innate immune response to sepsis. J Immunol 2010; 185(8): 4856–4862
https://doi.org/10.4049/jimmunol.1000404
pmid: 20844189
|
64 |
Croft M, So T, Duan W, Soroosh P. The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev 2009; 229(1): 173–191
https://doi.org/10.1111/j.1600-065X.2009.00766.x
pmid: 19426222
|
65 |
Zhang Y, Luo Y, Qin SL, Mu YF, Qi Y, Yu MH, Zhong M. The clinical impact of ICOS signal in colorectal cancer patients. OncoImmunology 2016; 5(5): e1141857
https://doi.org/10.1080/2162402X.2016.1141857
pmid: 27467961
|
66 |
Lines JL, Pantazi E, Mak J, Sempere LF, Wang L, O’Connell S, Ceeraz S, Suriawinata AA, Yan S, Ernstoff MS, Noelle R. VISTA is an immune checkpoint molecule for human T cells. Cancer Res 2014; 74(7): 1924–1932
https://doi.org/10.1158/0008-5472.CAN-13-1504
pmid: 24691993
|
67 |
Nowak EC, Lines JL, Varn FS, Deng J, Sarde A, Mabaera R, Kuta A, Le Mercier I, Cheng C, Noelle RJ. Immunoregulatory functions of VISTA. Immunol Rev 2017; 276(1): 66–79
https://doi.org/10.1111/imr.12525
pmid: 28258694
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|